TNG Pharmaceuticals Completes $4.6M Series A Financing

flyvaxTNG Pharmaceuticals, Inc., a Louisville, KY-based animal pharmaceutical company developing a vaccine for cattle to aid in control of the horn fly, completed a $4.6m Series A financing.

The round was led by the Yearling Fund, with participation from Angel Investor Investment Management Group, Bluegrass Angels, Commonwealth Seed Capital, LLC, Goose Society of Texas, the Ogle Foundation, Texas Halo Fund, the University of Louisville Foundation and other individual and institutional investors.

The company intends to use the funds to complete all phases of product development necessary to commercialize the vaccine.

Led by Serge Martinod (DVM, PhD), CEO, and Phoebe Wood, Executive Chairman, TNG is asvancing FlyVax™, a patented vaccine designed to reduce the damage caused by horn flies. The veterinary vaccine, first developed by research scientists at Auburn University and licensed by TNG, has been shown to be effective in initial laboratory testing.



Join the discussion